Amicogen, Inc. (KOSDAQ:092040)

Market Cap	200.08B
Revenue (ttm)	155.74B
Net Income (ttm)	-35.70B
Shares Out	54.82M
EPS (ttm)	-693.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,163
Average Volume	347,459
Open	4,190.00
Previous Close	4,205.00
Day's Range	4,075.00 - 4,245.00
52-Week Range	3,075.00 - 9,400.00
Beta	1.05
RSI	43.41
Earnings Date	Jan 31, 2025

About Amicogen

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. Th...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 225
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092040

Financial Performance

In 2023, Amicogen's revenue was 159.90 billion, an increase of 10.82% compared to the previous year's 144.30 billion. Losses were -23.29 billion, -50.68% less than in 2022.